HIV Specialist - March 2021 - 6

NEWS

I NFOR M AT ION FOR H I V CA RE PROV I DERS

IN
THE

Study Examines Attitudes Toward Long-Acting Injectable
HIV Therapy Among Women with a History of Injection

A

STUDY led by Columbia

University Mailman
School of Public Health
researchers examines attitudes
toward long-acting injectable (LAI)
HIV therapies, among women with
a history of injection-including
medical purposes and substance
use. The findings appear in the
journal AIDS Patient Care and STDs.
Currently, most HIV therapies
for treatment and prevention
(pre-exposure prophylaxis, PrEP)
necessitate daily pills, which pose
barriers to adherence. Recently,
however, LAI for HIV has emerged
as an alternative with the potential
to boost adherence, although little
research has been done on how
people with a history of injection feel
about these new forms of injectable

6 

MARCH 2021   HIVSPECIALIST  WWW.AAHIVM.ORG 

HIV therapy. There are 258,000
women in the United States living
with HIV.
The study involved interviews
with 89 women across six different
sites in the United States. Overall,
participants highlighted how LAIs
may improve adherence by freeing
women of treatment fatigue and
reminders associated with daily
pill-taking, thus eliminating potential
stigma, and facilitating confidentiality.
Most women with a history of
periodic injectable medication
(such as birth control) would prefer
LAI, but those with other frequent
injections (such as for diabetes)
who expressed a desire to limit the
number and frequency of injections
and clinic visits might not. Women
with a history of injection drug use

expressed mixed sentiments: some
feared LAI might trigger a recurrence
while others felt that familiarity with
needles would predispose people
who use injection drugs towards LAI.
The authors write that LAI HIV
therapies would ideally coincide with
existing LAI treatments (e.g., birth
control) to minimize inconvenience
and the need for multiple clinic visits,
an approach currently used in some
clinics that co-locate care for HIV and
substance use.
" Future research needs to address
injection-related concerns, and
develop patient-centered approaches
to help providers work with their
patients to best identify which
women could most benefit from
LAI use, " says first author Morgan
Philbin, PhD, assistant professor of
sociomedical sciences at Columbia
Mailman School. " As LAI ART for HIV
treatment and prevention is scaledup, systems must be created for
women and providers to collaborate
in order to best identify which women
might need additional support for
LAI use and which might be better
candidates for daily pills. "
The researchers conducted indepth interviews at six sites (New
York, NY; Chicago, IL; San Francisco,
CA; Atlanta, GA; Chapel Hill, NC;
Washington, D.C.) as part of the
Women's Interagency HIV Study,
including women living with HIV and
women at risk for HIV.
A complete list of authors, their
affiliations, and funding sources
is available online, as part of the
published article.

SHUTTERSTOCK/ MONKEY BUSINESS IMAGES


http://WWW.AAHIVM.ORG

HIV Specialist - March 2021

Table of Contents for the Digital Edition of HIV Specialist - March 2021

HIV Specialist - March 2021 - Cover1
HIV Specialist - March 2021 - Cover2
HIV Specialist - March 2021 - 1
HIV Specialist - March 2021 - 2
HIV Specialist - March 2021 - 3
HIV Specialist - March 2021 - 4
HIV Specialist - March 2021 - 5
HIV Specialist - March 2021 - 6
HIV Specialist - March 2021 - 7
HIV Specialist - March 2021 - 8
HIV Specialist - March 2021 - 9
HIV Specialist - March 2021 - 10
HIV Specialist - March 2021 - 11
HIV Specialist - March 2021 - 12
HIV Specialist - March 2021 - 13
HIV Specialist - March 2021 - 14
HIV Specialist - March 2021 - 15
HIV Specialist - March 2021 - 16
HIV Specialist - March 2021 - 17
HIV Specialist - March 2021 - 18
HIV Specialist - March 2021 - 19
HIV Specialist - March 2021 - 20
HIV Specialist - March 2021 - 21
HIV Specialist - March 2021 - 22
HIV Specialist - March 2021 - 23
HIV Specialist - March 2021 - 24
HIV Specialist - March 2021 - 25
HIV Specialist - March 2021 - 26
HIV Specialist - March 2021 - 27
HIV Specialist - March 2021 - 28
HIV Specialist - March 2021 - 29
HIV Specialist - March 2021 - 30
HIV Specialist - March 2021 - 31
HIV Specialist - March 2021 - 32
HIV Specialist - March 2021 - 33
HIV Specialist - March 2021 - 34
HIV Specialist - March 2021 - 35
HIV Specialist - March 2021 - 36
HIV Specialist - March 2021 - 37
HIV Specialist - March 2021 - 38
HIV Specialist - March 2021 - 39
HIV Specialist - March 2021 - 40
HIV Specialist - March 2021 - 41
HIV Specialist - March 2021 - 42
HIV Specialist - March 2021 - 43
HIV Specialist - March 2021 - 44
HIV Specialist - March 2021 - 45
HIV Specialist - March 2021 - 46
HIV Specialist - March 2021 - 47
HIV Specialist - March 2021 - 48
HIV Specialist - March 2021 - 49
HIV Specialist - March 2021 - 50
HIV Specialist - March 2021 - 51
HIV Specialist - March 2021 - 52
HIV Specialist - March 2021 - Cover3
HIV Specialist - March 2021 - Cover4
https://www.nxtbook.com/ygsreprints/AAHIVM/hiv-specialist-march-2021
https://www.nxtbook.com/ygsreprints/AAHIVM/G121337_AAHIV_122020
https://www.nxtbook.com/ygsreprints/AAHIVM/G119632_AAHIV_092020
https://www.nxtbook.com/ygsreprints/AAHIVM/G118334_AAHIV_062020
https://www.nxtbook.com/ygsreprints/AAHIVM/G116663_AAHIVM_032020
https://www.nxtbookmedia.com